ongoing research
innovative therapy developments
clinical trials and outcomes
published research
A small case series reports three neonatal epilepsy cases linked to vitamin B6 metabolism genes, reinforcing that early recognition and the right confirmatory testing can change outcomes. Pyridoxine-dependent epilepsy (PDE) is rare, but it is one of the most important “don’t-miss” causes of neonatal seizures because treatment can be effective. This report adds three more […]
A report of PDE-ALDH7A1 shows how early metabolic lab abnormalities can mimic other disorders, and how targeted biomarkers can quickly point back to a treatable B6-pathway epilepsy.
A review explains two lysine-breakdown routes in the body and argues that reducing flux through the saccharopine pathway could be therapeutic for PDE-ALDH7A1 and related disorders.
A case series summarizes seizure patterns, EEG changes, and ALDH7A1 variant findings in six children, emphasizing that early pyridoxine can normalize EEG and improve long-term outlook. Even within PDE-ALDH7A1, families can see very different seizure types and severity. This report reviews six children treated from 2017 to 2023, with most starting seizures in the neonatal […]
A neonatal case report describes multifocal seizures with severe metabolic instability and a confirmed ALDH7A1 pathogenic variant, stressing how urgent early recognition can be.
A methods-and-performance study supports adding PDE-ALDH7A1 to existing newborn screening systems by measuring 2-OPP and confirmatory markers in a single FIA-MS/MS assay.
A center cohort study tracks biochemical changes and practical adherence issues with lysine reduction therapies in 17 PDE-ALDH7A1 patients.
A mouse genetics study shows that disrupting lysine alpha-ketoglutarate reductase (LKR) upstream of ALDH7A1 can eliminate toxic intermediates and reverse seizures and cognitive deficits in an ALDH7A1-deficient model.
A systematic review compares pyridoxine alone versus adding lysine-restricted diet and/or arginine, with a focus on seizure control and neurodevelopmental outcomes.
© 2023 Cure PDE Foundation | All Rights Reserved | Terms of Use | Privacy Policy | Site Credit